Gamma-secretase modulator 2 is primarily investigated for its potential therapeutic applications in neurodegenerative diseases, particularly Alzheimer's disease. It works by modulating the activity of gamma-secretase, an enzyme involved in the production of amyloid-beta peptides. By altering the enzyme's function, it aims to reduce the formation of toxic amyloid-beta plaques, which are a hallmark of Alzheimer's pathology. This compound is being studied for its ability to provide a more targeted approach compared to traditional gamma-secretase inhibitors, potentially minimizing adverse effects. Additionally, research is exploring its use in treating certain types of cancer by inhibiting gamma-secretase-related signaling pathways, which may help slow the growth of cancer cells. Ongoing studies evaluate its efficacy, safety, and potential as a treatment option for Alzheimer's, related conditions, and oncology applications.